America Great Health (AAGH)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -492.64 Thousand USD | 89.59% |
| 2022 | -4.73 Million USD | -1843.71% |
| 2021 | -243.56 Thousand USD | -427.75% |
| 2020 | -46.15 Thousand USD | 1.33% |
| 2019 | -46.77 Thousand USD | 19.57% |
| 2018 | -58.14 Thousand USD | -20.23% |
| 2017 | -48.36 Thousand USD | 95.76% |
| 2016 | -1.14 Million USD | -72.89% |
| 2015 | -660.09 Thousand USD | -9.0% |
| 2014 | -605.61 Thousand USD | -464.02% |
| 2013 | -107.37 Thousand USD | -90.85% |
| 2012 | -56.26 Thousand USD | -155.45% |
| 2011 | -22.02 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -153.86 Thousand USD | -105.33% |
| 2024 Q3 | -134.26 Thousand USD | 12.74% |
| 2024 Q1 | -74.93 Thousand USD | 52.45% |
| 2023 Q4 | -157.58 Thousand USD | -41.03% |
| 2023 FY | -492.64 Thousand USD | 89.59% |
| 2023 Q1 | -128.22 Thousand USD | 93.7% |
| 2023 Q2 | -95.1 Thousand USD | 25.83% |
| 2023 Q3 | -111.73 Thousand USD | -17.48% |
| 2022 Q2 | -1.75 Million USD | -488.27% |
| 2022 FY | -4.73 Million USD | -1843.71% |
| 2022 Q4 | -2.03 Million USD | -214.45% |
| 2022 Q3 | -647.25 Thousand USD | 63.09% |
| 2022 Q1 | -298.06 Thousand USD | -102.26% |
| 2021 Q3 | -13.41 Million USD | -38627.57% |
| 2021 Q4 | 13.2 Million USD | 198.45% |
| 2021 FY | -243.56 Thousand USD | -427.75% |
| 2021 Q1 | -1182.00 USD | 96.37% |
| 2021 Q2 | -34.63 Thousand USD | -2830.54% |
| 2020 FY | -46.15 Thousand USD | 1.33% |
| 2020 Q4 | -32.53 Thousand USD | -2095.01% |
| 2020 Q3 | -1482.00 USD | 85.16% |
| 2020 Q2 | -9986.00 USD | -363.82% |
| 2020 Q1 | -2153.00 USD | 75.66% |
| 2019 Q4 | -8844.00 USD | -17.43% |
| 2019 Q3 | -7531.00 USD | 69.3% |
| 2019 FY | -46.77 Thousand USD | 19.57% |
| 2019 Q1 | -5868.00 USD | 72.15% |
| 2019 Q2 | -24.52 Thousand USD | -318.0% |
| 2018 Q2 | -15.07 Thousand USD | -16.81% |
| 2018 FY | -58.14 Thousand USD | -20.23% |
| 2018 Q4 | -21.07 Thousand USD | -131.57% |
| 2018 Q3 | -9099.00 USD | 39.64% |
| 2018 Q1 | -12.9 Thousand USD | 73.32% |
| 2017 Q2 | -860.69 Thousand USD | -1913.61% |
| 2017 Q1 | -42.74 Thousand USD | 19.31% |
| 2017 Q3 | 12.12 Thousand USD | 101.41% |
| 2017 Q4 | -48.36 Thousand USD | -498.93% |
| 2017 FY | -48.36 Thousand USD | 95.76% |
| 2016 Q2 | -130.06 Thousand USD | 80.97% |
| 2016 Q3 | -274.79 Thousand USD | -111.27% |
| 2016 Q1 | -683.38 Thousand USD | -273.64% |
| 2016 Q4 | -52.97 Thousand USD | 80.72% |
| 2016 FY | -1.14 Million USD | -72.89% |
| 2015 Q2 | -159.62 Thousand USD | -0.52% |
| 2015 Q4 | -182.9 Thousand USD | -15.19% |
| 2015 Q3 | -158.78 Thousand USD | 0.53% |
| 2015 Q1 | -158.79 Thousand USD | 60.7% |
| 2015 FY | -660.09 Thousand USD | -9.0% |
| 2014 Q3 | -151.69 Thousand USD | -204.05% |
| 2014 Q1 | 20.49 Thousand USD | 132.46% |
| 2014 Q4 | -404.03 Thousand USD | -166.35% |
| 2014 FY | -605.61 Thousand USD | -464.02% |
| 2014 Q2 | -49.89 Thousand USD | -343.49% |
| 2013 Q2 | -18.19 Thousand USD | -50.39% |
| 2013 Q4 | -63.11 Thousand USD | -367.72% |
| 2013 Q3 | -13.49 Thousand USD | 25.82% |
| 2013 Q1 | -12.09 Thousand USD | 75.39% |
| 2013 FY | -107.37 Thousand USD | -90.85% |
| 2012 Q2 | -2684.00 USD | -140.07% |
| 2012 Q3 | -4417.00 USD | -64.57% |
| 2012 Q1 | -1118.00 USD | 39.53% |
| 2012 Q4 | -49.16 Thousand USD | -1012.97% |
| 2012 FY | -56.26 Thousand USD | -155.45% |
| 2011 FY | -22.02 Thousand USD | 0.0% |
| 2011 Q4 | -1849.00 USD | -496.45% |
| 2011 Q3 | -310.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | 75.543% |
| Innovation1 Biotech Inc. | -1.36 Million USD | 63.972% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -531.457% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 52.946% |